Table 1.
Characteristics of patients in the training and validation cohorts
| Characteristics n (%/mean±SD) | Training cohort (n=124) |
Validation cohort (n=71) |
||||
|---|---|---|---|---|---|---|
| Feeding intolerance (n=49) | Feeding tolerance (n=75) | P | Feeding intolerance (n=37) | Feeding tolerance (n=34) | P | |
| Age, years | 65.9 (20.2) | 67.2 (15.0) | 0.088 | 72.8 (13.3) | 70.1 (14.4) | 0.463 |
| Sex (male) | 39 (79.5%) | 49 (65.3%) | 0.089 | 29 (78.4%) | 20 (60.6%) | 0.128 |
| Comorbidity | ||||||
| Diabetes | 16 (32.6%) | 31 (41.3%) | 0.330 | 6 (16.2%) | 7 (21.2%) | 0.866 |
| Hypertension | 32 (65.3%) | 48 (64.0%) | 0.882 | 16 (43.2%) | 11 (33.3%) | 0.484 |
| Coronary heart disease | 6 (12.2%) | 13 (17.3%) | 0.442 | 7 (18.9%) | 10 (30.3%) | 0.449 |
| Chronic pulmonary disease | 6 (12.2%) | 8 (10.6%) | 0.786 | 3 (8.1%) | 5 (15.2%) | 0.615 |
| Chronic kidney failure | 11 (22.4%) | 14 (18.6%) | 0.776 | 2 (5.4%) | 5 (15.2%) | 0.360 |
| Cerebrovascular accident | 18 (36.7%) | 25 (33.3%) | 0.845 | 16 (43.2%) | 10 (30.3%) | 0.336 |
| Ventilation | 43 (87.8%) | 63 (84.0%) | 0.749 | 24 (64.9%) | 18 (54.5%) | 0.436 |
| Infection | ||||||
| Pneumonia | 47 (95.9%) | 70 (93.3%) | 0.832 | 34 (91.9%) | 22 (66.7%) | 0.012 |
| Urinary tract infection | 6 (12.2%) | 7 (9.3%) | 0.828 | 1 (2.7%) | 4 (12.1%) | 0.305 |
| Intracranial infection | 1 (2.0%) | 3 (4.0%) | 0.933 | 0 (0%) | 2 (6.1%) | 0.436 |
| Blood infection | 5 (10.2%) | 8 (10.6%) | 1.000 | 2 (5.4%) | 2 (6.1%) | 1.000 |
| Abdominal infection | 1 (2.0%) | 1 (1.3%) | 1.000 | 2 (5.4%) | 0 (0%) | 0.511 |
| Skin infection | 3 (6.1%) | 3 (4.0%) | 0.912 | 3 (8.1%) | 6 (18.2%) | 0.395 |
| APACHE II score | 23.2 (6.7) | 22.6 (7.6) | 0.730 | 22.2 (7.4) | 23.6 (4.7) | 0.430 |
| Feeding method | ||||||
| Intermittent | 6 (12.25%) | 17 (22.67%) | 0.221 | 21 (56.76%) | 29 (85.2%) | 0.018 |
| Bolus | 43 (87.75%) | 58 (77.33%) | 0.221 | 16 (43.24%) | 5 (14.71%) | 0.018 |
| Feeding route | ||||||
| Gastric tube | 40 (81.63%) | 71 (94.67%) | 0.044 | 35 (94.59%) | 34 (100%) | 0.511 |
| Jejunal tube | 9 (18.37%) | 4 (5.33%) | 0.044 | 2 (5.41%) | 0 (0%) | 0.511 |
| Total EN (mL) | 580 (200-1000) | 630 (200-1500) | 0.688 | 680 (200-1000) | 700 (200-1000) | 0.783 |
| Gastric motility drugs | 17 (34.69%) | 7 (9.33%) | 0.001 | 7 (18.91%) | 3 (8.82%) | 0.379 |
| Sedation | 45 (91.84%) | 64 (85.33%) | 0.421 | 34 (91.89%) | 30 (88.23%) | 0.906 |
| 28-day mortality | 2 (4.1%) | 4 (5.3%) | 1.000 | 4 (10.8%) | 2 (6.1%) | 0.750 |
EN, enteral nutrition; SD, standard deviation; APACHE II, Acute Physiology and Chronic Health Evaluation II